Perrigo

Perrigo is a leading global provider of over-the-counter health and wellness products, as well as generic prescription pharmaceuticals. Headquartered in Dublin, Ireland, for corporate and tax purposes, its principal executive offices are located in Grand Rapids, Michigan. The company operates as one of the world's largest manufacturers of store brand consumer self-care products, supplying major retailers, wholesalers, and drug distributors across the globe.

History

The company's origins trace back to 1887 when druggist Luther Perrigo purchased a drugstore in Allegan, Michigan. For decades, it operated as a regional pharmacy chain and wholesaler. A significant transformation began in the 1980s under the leadership of Michael Jandernoa, who shifted the focus toward manufacturing private label OTC medications. This strategy fueled rapid growth through a series of acquisitions, including the OTC businesses of Lederle Laboratories and Bristol-Myers Squibb. A pivotal moment came in 2005 with the acquisition of Agis Industries, which significantly expanded its generic pharmaceutical operations, particularly in Israel. In a major corporate restructuring, Perrigo executed a tax inversion in 2013, acquiring Elan Corporation and reincorporating in Ireland. Further expansion followed with the landmark $4.5 billion acquisition of Omega Pharma in 2015, substantially increasing its consumer health presence in Europe.

Products and operations

Perrigo's business is organized into two primary segments: Consumer Healthcare and Prescription Pharmaceuticals. The Consumer Healthcare division is a global leader in self-care, producing a vast portfolio of store brand OTC products. Key categories include analgesics like acetaminophen and ibuprofen, cough and cold remedies, gastrointestinal treatments, vitamins, minerals, and supplements, infant formula, and smoking cessation aids such as nicotine gum. Its Prescription Pharmaceuticals segment develops, manufactures, and markets generic prescription drugs in various dosage forms, including topicals, orals, and transdermals, primarily for the United States market. The company also maintains an Animal health unit. Its products are sold under retailer-owned labels at major chains like Walmart, CVS Health, Walgreens Boots Alliance, and Tesco, as well as under its own brands, which include GoodSense, Famous, and Queen Helene.

Corporate affairs

Perrigo is a public company with its ordinary shares listed on both the New York Stock Exchange and the Tel Aviv Stock Exchange. Its corporate domicile is in Dublin, Ireland, while its main operational and executive leadership remains based in the United States, specifically in Michigan. The company is governed by a Board of directors chaired by Rolf Classon, with Patrick Lockwood-Taylor serving as President and Chief executive officer. Perrigo maintains a significant global manufacturing and research footprint with facilities across the United States, Israel, the United Kingdom, Belgium, Germany, Australia, and China. Its operational strategy emphasizes R&D for product line extensions, ANDAs for generic drugs, and supply chain excellence to serve its large retail partners.

Legal and regulatory issues

The company has navigated numerous complex legal and regulatory challenges inherent to the pharmaceutical industry. A major ongoing issue involves widespread litigation related to its role as a major manufacturer of store brand infant formula, facing numerous lawsuits alleging contamination with *Cronobacter* and Salmonella. Perrigo has also been involved in significant antitrust litigation, including a class-action suit concerning delayed market entry of a generic version of Propecia. Like many generic drugmakers, it has faced scrutiny from the U.S. Department of Justice and the U.S. Securities and Exchange Commission under the Foreign Corrupt Practices Act. Furthermore, the company has engaged in various patent litigation cases, such as defending its ANDA for a generic version of Suboxone against Indivior.

Financial performance

As a major player in the consumer staples sector, Perrigo's financial performance is closely watched by investors. For the fiscal year 2023, the company reported net sales of approximately $4.65 billion. Historically, its revenue growth has been driven by strategic acquisitions, organic growth in key OTC categories, and market share gains in the generic pharmaceutical space. The company's financial strategy has focused on deleveraging following major acquisitions, while also investing in brand marketing for its owned brands and capacity expansion. It provides regular financial guidance and reports to the U.S. Securities and Exchange Commission, with its stock performance often influenced by earnings reports, FDA approval milestones for generic drugs, and resolutions of major litigation.

Category:Pharmaceutical companies of Ireland Category:Companies listed on the New York Stock Exchange Category:Companies based in Michigan Category:Manufacturing companies established in 1887